Last reviewed · How we verify
GSK2245035 Nasal Spray Solution
At a glance
| Generic name | GSK2245035 Nasal Spray Solution |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Effect of the GSK2245035 on the Allergen-induced Asthmatic Response (PHASE2)
- A Safety and Efficacy Study of Intranasal GSK2245035 in Adults With Allergic Asthma (PHASE2)
- A Study to Investigate the Safety and Pharmacodynamics of Repeat Intranasal Administration of the TLR7 Agonist GSK2245035 in Subjects With Respiratory Allergies (PHASE2)
- To Investigate the Safety, Pharmacodynamics and Effect on Allergic Reactivity of the Toll-like Receptor 7 (TLR7) Agonist GSK2245035 in Subjects With Respiratory Allergies (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |